- Home
- GOGL vs IRON Comparison
GOGL vs IRON Comparison
Compare GOGL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOGL
- IRON
- Stock Information
- Founded
- GOGL N/A
- IRON 2017
- Country
- GOGL Bermuda
- IRON United States
- Employees
- GOGL N/A
- IRON N/A
- Industry
- GOGL Marine Transportation
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- GOGL Consumer Discretionary
- IRON Health Care
- Exchange
- GOGL Nasdaq
- IRON Nasdaq
- Market Cap
- GOGL 1.8B
- IRON 1.9B
- IPO Year
- GOGL 1997
- IRON N/A
- Fundamental
- Price
- GOGL $9.43
- IRON $54.53
- Analyst Decision
- GOGL Hold
- IRON Strong Buy
- Analyst Count
- GOGL 2
- IRON 10
- Target Price
- GOGL $12.25
- IRON $74.40
- AVG Volume (30 Days)
- GOGL 1.8M
- IRON 329.3K
- Earning Date
- GOGL 02-26-2025
- IRON 03-20-2025
- Dividend Yield
- GOGL 12.69%
- IRON N/A
- EPS Growth
- GOGL 102.13
- IRON N/A
- EPS
- GOGL 1.22
- IRON N/A
- Revenue
- GOGL $1,011,652,000.00
- IRON N/A
- Revenue This Year
- GOGL N/A
- IRON N/A
- Revenue Next Year
- GOGL N/A
- IRON N/A
- P/E Ratio
- GOGL $7.96
- IRON N/A
- Revenue Growth
- GOGL 14.81
- IRON N/A
- 52 Week Low
- GOGL $8.52
- IRON $25.60
- 52 Week High
- GOGL $15.77
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- GOGL 53.15
- IRON 41.25
- Support Level
- GOGL $9.41
- IRON $52.21
- Resistance Level
- GOGL $9.73
- IRON $55.89
- Average True Range (ATR)
- GOGL 0.21
- IRON 1.86
- MACD
- GOGL 0.04
- IRON 0.20
- Stochastic Oscillator
- GOGL 61.36
- IRON 48.48
About GOGL Golden Ocean Group Limited
Golden Ocean Group Ltd is a Bermuda-based dry bulk shipping company. Its business involves the transportation of dry bulk cargo including ores, coal, grains and fertilizers through its fleet of owned and chartered vessels, bareboat vessels, commercial management vessels and new buildings are chartered-out on fixed rate time charters and index-linked time charter contracts.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.